Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)
- 442 Downloads
Three patients under hemodialysis (HD) with relapsed/refractory multiple myeloma (MM) were administered panobinostat/bortezomib/dexamethasone (FVD). Case 1: The patient was a 66-year-old male with BJP-κ. FVD was effective, but HD could not be discontinued. He developed Grade 3 adverse events (AEs), including nausea, dehydration, and fatigue, following the common terminology criteria for adverse events v4.0. FVD was discontinued after the third course, while HD was continued. Case 2: The patient was a 65-year-old female with IgG-λ + BJP-λ. Amyloidosis was complicated. The first course of FVD was effective, but HD could not be discontinued. She developed G2 AEs, including nausea and fatigue. The cardiac amyloidosis worsened, and she died of heart and renal failure. Case 3: The patient was a 79-year-old male with BJP-κ. FVD was effective, and the HD could be discontinued on day 12 of treatment. No AEs were noted. However, he declined continuation of the FVD and died of MM relapse and renal failure. We analyzed the pharmacokinetics of panobinostat. There were no correlations between dose level and blood level of panobinostat or between blood level, efficacy, and incidence of AEs. We additionally measured the rate of elimination of the drug by HD.
KeywordsRelapsed/refractory multiple myeloma Renal failure Hemodialysis Panobinostat/bortezomib/dexamethasone (FVD) therapy
Compliance with ethical standard
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206. doi: 10.1016/S1470-2045(14)70440-1 (Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015; 16(1): e6).CrossRefPubMedGoogle Scholar
- 2.Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol. 2015;75(1):87–95. doi: 10.1007/s00280-014-2612-8 (Epub 2014 Nov 7).CrossRefPubMedGoogle Scholar
- 3.A guide to proper use. Novartis oncology.Google Scholar
- 4.Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J,et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012; 26(1): 149–57. doi: 10.1038/leu.2011.196. (Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May; 26(5): 1153. Nari, Hareth [corrected to Nahi, Hareth]).
- 5.Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331–7. doi: 10.1182/blood-2013-01-481325 (Epub 2013 Aug 15).CrossRefPubMedGoogle Scholar